Cochrane · systematic review · CD008074
Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation)
Ostinelli, EG, Jajawi, S, Spyridi, S, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
20
current version
GRADE rated
13
No studies
7
Included studies
NR
No studies 7 · 35%Ungraded 0 · 0%Very low 8 · 40%Low 5 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
ARIPIPRAZOLE (IM) compared to PLACEBO/NIL for psychosis‐induced aggression or agitation (rapid tranquillisation)
Population: psychosis‐induced aggression or agitation (rapid tranquillisation)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tranquillisation or asleep ARIPIPRAZOLE (IM) vs PLACEBO/NIL | no estimate extracted | NR | No studies |
Repeated need for tranquillisation ‐ needing additional injections during 24 hours ARIPIPRAZOLE (IM) vs PLACEBO/NIL | RR 0.69 [0.56, 0.85] | 2 studies · 382 participants | Very low Downgraded: risk of bias |
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours ARIPIPRAZOLE (IM) vs PLACEBO/NIL | RR 1.5 [1.17, 1.92] | 2 studies · 382 participants | Very low Downgraded: risk of bias |
Global state: non‐responders to the first injection ARIPIPRAZOLE (IM) vs PLACEBO/NIL | RR 0.49 [0.34, 0.71] | 1 study · 263 participants | Low Downgraded: risk of bias, indirectness |
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) ARIPIPRAZOLE (IM) vs PLACEBO/NIL | RR 1.51 [0.93, 2.46] | 1 study · 117 participants | Very low Downgraded: risk of bias |
Economic outcomes ARIPIPRAZOLE (IM) vs PLACEBO/NIL | no estimate extracted | NR | No studies |
ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis‐induced aggression or agitation (rapid tranquillisation)
Population: psychosis‐induced aggression or agitation (rapid tranquillisation)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tranquillisation or asleep ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL | no estimate extracted | NR | No studies |
Repeated need for tranquillisation ‐ needing additional injections during 24 hours ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL | RR 1.28 [1, 1.63] | 2 studies · 477 participants | Very low Downgraded: risk of bias |
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL | RR 0.94 [0.8, 1.11] | 2 studies · 477 participants | Very low Downgraded: risk of bias |
Global state: non‐responders to the first injection ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL | RR 1.18 [0.78, 1.79] | 1 study · 360 participants | Low Downgraded: risk of bias, indirectness |
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL | RR 0.91 [0.61, 1.35] | 1 study · 113 participants | Very low Downgraded: risk of bias |
Adverse effects: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL | RR 0.29 [0.12, 0.7] | 2 studies · 471 participants | Very low Downgraded: risk of bias |
Economic outcomes ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL | no estimate extracted | NR | No studies |
ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis‐induced aggression or agitation (rapid tranquillisation)
Population: psychosis‐induced aggression or agitation (rapid tranquillisation)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tranquillisation or asleep ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE | no estimate extracted | NR | No studies |
Repeated need for tranquillisation ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE | no estimate extracted | NR | No studies |
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE | RR 0.77 [0.6, 0.99] | 1 study · 80 participants | Low Downgraded: imprecision |
Global state: CGI‐S change score up to 2 hours ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE | no estimate extracted | 1 study · 80 participants | Low Downgraded: imprecision |
Adverse effects: one or more adverse effects during 24 hours ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE | RR 0.75 [0.45, 1.24] | 1 study · 80 participants | Very low Downgraded: imprecision, indirectness |
Adverse effects: somnolence during 24 hours ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE | RR 0.25 [0.08, 0.82] | 1 study · 80 participants | Low Downgraded: imprecision |
Economic outcomes ARIPIPRAZOLE (IM) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE | no estimate extracted | NR | No studies |